Arcellx (ACLX) Net Cash Flow (2021 - 2025)
Arcellx's quarterly Net Cash Flow came in at $1.3 million in Q4 2025, up 102.24% year-on-year from $621545.0 in Q4 2024, and down 92.55% quarter-over-quarter from $16.9 million in Q3 2025.
Arcellx has reported Net Cash Flow for 5 years, with the latest figure at $1.3 million in Q4 2025.
- For the quarter ending Q4 2025, Net Cash Flow rose 102.24% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2025 stood at -$25.4 million (up 91.25% YoY), and the FY2025 full-year result was -$25.4 million, up 91.25% from the prior year.
- Net Cash Flow for Q4 2025 stood at $1.3 million, down from $16.9 million in the prior quarter.
- The five-year high for Net Cash Flow was $267.9 million in Q4 2023, with the low at -$241.7 million in Q1 2024.
- Average Net Cash Flow over 5 years is $1.8 million, with a median of $4.3 million recorded in 2022.
- Year-over-year, Net Cash Flow soared 3511.87% in 2023 and plunged 289.58% in 2024.
- Tracing ACLX's Net Cash Flow over 5 years: stood at -$39.2 million in 2021, then jumped by 118.92% to $7.4 million in 2022, then soared by 3511.87% to $267.9 million in 2023, then tumbled by 120.97% to -$56.2 million in 2024, then soared by 102.24% to $1.3 million in 2025.
- The last three Net Cash Flow figures came in at $1.3 million (Q4 2025), $16.9 million (Q3 2025), and -$18.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 1.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.26 Mn |
| Dec 31, 2025 | 1.26 Mn |
| Sep 30, 2025 | 16.87 Mn |
| Sep 30, 2025 | 16.87 Mn |
| Jun 30, 2025 | -18.73 Mn |
| Jun 30, 2025 | -18.73 Mn |
| Mar 31, 2025 | -24.82 Mn |
| Mar 31, 2025 | -24.82 Mn |
| Dec 31, 2024 | -56.17 Mn |
| Dec 31, 2024 | -56.17 Mn |
| Sep 30, 2024 | 61.82 Mn |
| Sep 30, 2024 | 61.82 Mn |
| Jun 30, 2024 | -54.55 Mn |
| Jun 30, 2024 | -54.55 Mn |
| Mar 31, 2024 | -241.70 Mn |
| Mar 31, 2024 | -241.70 Mn |
| Dec 31, 2023 | 267.86 Mn |
| Dec 31, 2023 | 267.86 Mn |
| Sep 30, 2023 | -175.12 Mn |
| Sep 30, 2023 | -175.12 Mn |
| Jun 30, 2023 | 28.77 Mn |
| Jun 30, 2023 | 28.77 Mn |
| Mar 31, 2023 | 210.71 Mn |
| Mar 31, 2023 | 210.71 Mn |
| Dec 31, 2022 | 7.42 Mn |
| Dec 31, 2022 | 7.42 Mn |
| Sep 30, 2022 | -107.78 Mn |
| Sep 30, 2022 | -107.78 Mn |
| Jun 30, 2022 | 39.68 Mn |
| Jun 30, 2022 | 39.68 Mn |
| Mar 31, 2022 | 96.33 Mn |
| Mar 31, 2022 | 96.33 Mn |
| Dec 31, 2021 | -39.19 Mn |
| Dec 31, 2021 | -39.19 Mn |
| Sep 30, 2021 | -73.76 Mn |
| Sep 30, 2021 | -73.76 Mn |
| Jun 30, 2021 | 26.13 Mn |
| Jun 30, 2021 | 26.13 Mn |
| Mar 31, 2021 | 71.06 Mn |
| Mar 31, 2021 | 71.06 Mn |